Your browser doesn't support javascript.
loading
A general approach for selection of epitope-directed binders to proteins.
Zhou, Jie; Le, Chau Q; Zhang, Yun; Wells, James A.
Afiliação
  • Zhou J; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.
  • Le CQ; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.
  • Zhang Y; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.
  • Wells JA; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.
Proc Natl Acad Sci U S A ; 121(19): e2317307121, 2024 May 07.
Article em En | MEDLINE | ID: mdl-38683990
ABSTRACT
Directing antibodies to a particular epitope among many possible on a target protein is a significant challenge. Here, we present a simple and general method for epitope-directed selection (EDS) using a differential phage selection strategy. This involves engineering the protein of interest (POI) with the epitope of interest (EOI) mutated using a systematic bioinformatics algorithm to guide the local design of an EOI decoy variant. Using several alternating rounds of negative selection with the EOI decoy variant followed by positive selection on the wild-type POI, we were able to identify highly specific and potent antibodies to five different EOI antigens that bind and functionally block known sites of proteolysis. Among these, we developed highly specific antibodies that target the proteolytic site on the CUB domain containing protein 1 (CDCP1) to prevent its proteolysis allowing us to study the cellular maturation of this event that triggers malignancy. We generated antibodies that recognize the junction between the pro- and catalytic domains for three different matrix metalloproteases (MMPs), MMP1, MMP3, and MMP9, that selectively block activation of each of these enzymes and impair cell migration. We targeted a proteolytic epitope on the cell surface receptor, EPH Receptor A2 (EphA2), that is known to transform it from a tumor suppressor to an oncoprotein. We believe that the EDS method greatly facilitates the generation of antibodies to specific EOIs on a wide range of proteins and enzymes for broad therapeutic and diagnostic applications.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Epitopos Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Epitopos Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article